Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck HPV Vaccine Gardasil Shows 100% Efficacy In Phase III Primary Analysis

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck plans to submit a BLA for the cervical cancer vaccine in the fourth quarter.

You may also be interested in...



Merck Takes A Shot At A June Approval For HPV Vaccine Gardasil

The firm requests a priority review for the human papillomavirus vaccine’s BLA, submitted Dec. 1.

Merck Takes A Shot At A June Approval For HPV Vaccine Gardasil

The firm requests a priority review for the human papillomavirus vaccine’s BLA, submitted Dec. 1.

Teen Vaccine Approvals Increasing, FDA Says

The agency is observing a rise in the number of vaccines targeted at adolescents, CBER Vaccine Research & Review Director Baylor says. Two vaccines for use in adolescents – Menactra and Boostrix – have been approved so far this year; a third, Adacel, has a user fee date of June 11.

Related Content

Topics

UsernamePublicRestriction

Register

PS061222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel